去年，United Therapeutics Corp表现最佳的业务板块Tyvaso DPI实现营收1.29B美元。United States的营收贡献最高，去年达到3.04B美元。最近一个季度，截至2026-06-30，United Therapeutics Corp表现最佳的业务板块Tyvaso DPI实现营收326.60M美元。United States的营收贡献最高，达到783.30M美元。

业务

营业收入

占比

年报

年报

单季报

Tyvaso DPI

Nebulized Tyvaso

Remodulin

Orenitram

Unituxin

Adcirca

Other

Tyvaso

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Tyvaso DPI

1.29B(40.59%)

1.03B(35.92%)

731.10M(31.41%)

--(--)

Nebulized Tyvaso

585.70M(18.40%)

586.80M(20.39%)

502.60M(21.59%)

--(--)

Remodulin

526.80M(16.55%)

538.10M(18.70%)

494.80M(21.26%)

500.20M(25.83%)

513.70M(30.48%)

516.70M(34.83%)

587.00M(40.52%)

599.00M(36.80%)

Orenitram

496.90M(15.61%)

434.30M(15.09%)

359.40M(15.44%)

325.10M(16.79%)

306.10M(18.16%)

293.10M(19.76%)

225.30M(15.55%)

205.10M(12.60%)

Unituxin

226.80M(7.13%)

238.70M(8.30%)

198.90M(8.55%)

182.90M(9.45%)

202.30M(12.00%)

122.90M(8.29%)

113.70M(7.85%)

84.80M(5.21%)

Adcirca

30.00M(0.94%)

23.80M(0.83%)

28.90M(1.24%)

41.30M(2.13%)

55.90M(3.32%)

67.30M(4.54%)

107.20M(7.40%)

323.70M(19.89%)

Other

24.00M(0.75%)

22.10M(0.77%)

11.80M(0.51%)

13.80M(0.71%)

--(--)

Tyvaso

700.00K(0.02%)

--(--)

873.00M(45.09%)

607.50M(36.04%)

483.30M(32.58%)

415.60M(28.69%)

415.20M(25.51%)

地区

营业收入

占比

年报

年报

单季报

United States

Rest of World

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

United States

3.04B(95.42%)

2.74B(95.21%)

2.20B(94.62%)

1.81B(93.69%)

1.56B(92.80%)

1.41B(95.20%)

1.32B(91.33%)

1.53B(93.88%)

1.54B(89.07%)

1.46B(91.44%)

1.35B(92.31%)

1.18B(91.64%)

1.03B(92.43%)

846.61M(92.42%)

676.97M(91.09%)

Rest of World

145.70M(4.58%)

137.70M(4.79%)

125.30M(5.38%)

122.20M(6.31%)

121.30M(7.20%)

71.20M(4.80%)

125.60M(8.67%)

99.60M(6.12%)

188.50M(10.93%)

136.90M(8.56%)

112.76M(7.69%)

107.76M(8.36%)

84.55M(7.57%)

69.47M(7.58%)

66.22M(8.91%)